Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial

医学 随机对照试验 内科学 对偶(语法数字) 心脏病学 急性冠脉综合征 临床试验 冠心病 梅德林 心肌梗塞 随机化 经皮冠状动脉介入治疗 外科
作者
Sergio Raposeiras‐Roubín,Emad Abu Assi,César Jiménez Méndez,Ester Mínguez de la Guía,Jose-Ángel Pérez-Rivera,Marta Marcos Mangas,Ana Ayesta,Aitor Uribarri,Pablo Jorge‐Pérez,Pablo Antúnez‐Muiños,Clara Bonanad Lozano,Anna Carrasquer,Ana Viana‐Tejedor,Pablo Domínguez Erquicia,Alberto Villar Ruiz,Macarena López Vázquez,Lara Aguilar‐Iglesias,Alberto Alén Andrémar,María Vidal‐Burdeus,Marta María Martín Cabeza
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:153 (3): 140-149 被引量:4
标识
DOI:10.1161/circulationaha.125.075388
摘要

BACKGROUND: Current guidelines recommend a stepwise strategy to achieve low-density lipoprotein cholesterol (LDL-C) goals after acute coronary syndrome (ACS). Earlier intensive strategies based on a combination of lipid-lowering therapies (LLTs) could be useful from the onset of ACS. However, the role of bempedoic acid in ACS, particularly when combined with high-intensity statins and ezetimibe, remains uncertain. The aim of ES-BempedACS (Efficacy and Security of Bempedoic Acid in Acute Coronary Syndrome) was to compare the efficacy and safety of triple LLT (high-dose, high-intensity statin+ezetimibe+bempedoic acid) versus standard of care (high-dose, high-intensity statin+ezetimibe) after ACS. METHODS: ES-BempedACS is a multicenter, independent, pragmatic, prospective, randomized, open, blinded end point controlled trial conducted in 12 Spanish hospitals between November 2023 and October 2024. The primary end point was the proportion of patients achieving LDL-C <55 mg/dL (<1.4 mmol/L) at 8 weeks after ACS, comparing triple LLT with standard of care. RESULTS: A total of 206 patients (59.5±10.9 years of age [mean±SD]; 21.4% women) were randomized within the first 72 hours of ACS to triple LLT or standard therapy of high-intensity statin+ezetimibe (ie, dual LLT). The baseline LDL-C level was 133.6±28.8 mg/dL. After 8 weeks, the LDL-C level was reduced to <55 mg/dL in 59.4% of patients in the triple LLT group compared with 53.1% in the control group (dual LLT; P =0.376). The percentage change in LDL-C level was 57.5±17.8% and 56.9±18.5% in the triple and dual LLT groups, respectively ( P =0.823). Triple versus dual LLT showed similar results in reduction of non–high-density lipoprotein cholesterol levels (49.0±25.4 in triple LLT versus 49.1±31.2 in dual LLT; P =0.970) and triglyceride levels (14.9±36.9 in triple LLT versus 16.8±36.0 in dual LLT;) P =0.718), without differences in adverse events. CONCLUSIONS: Both dual and triple LLT after ACS allow for high rates (>50%) of adequate LDL-C control (<55 mg/dL) at 8 weeks. Adding bempedoic acid to statin–ezetimibe therapy in the setting of ACS is safe but failed to improve the percentage of patients achieving the LDL-C goal (<55 mg/dL) at 8 weeks. Larger, randomized studies are needed to confirm our findings. REGISTRATION: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2021-006550-31.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
炙热夏寒完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
chengcheng完成签到,获得积分10
3秒前
3秒前
aaa发布了新的文献求助10
3秒前
郑博发布了新的文献求助30
4秒前
5秒前
5秒前
5秒前
5秒前
5秒前
lll发布了新的文献求助10
6秒前
张安安完成签到,获得积分10
6秒前
天天快乐的应助被遇晨采纳,获得10
6秒前
6秒前
XIaoLuzi完成签到,获得积分10
7秒前
7秒前
biowzf发布了新的文献求助10
7秒前
369ninja发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
10秒前
10秒前
10秒前
科目三的应助被知有采纳,获得10
11秒前
共享精神的应助被xh采纳,获得10
11秒前
大脸喵发布了新的文献求助30
12秒前
sfdg完成签到,获得积分10
12秒前
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814